RecruitingPhase 4NCT05758701

CT TAVR Abdomen Study

Dual Energy CT Decreased IV Contrast Dose Imaging for TAVR


Sponsor

University of Maryland, Baltimore

Enrollment

164 participants

Start Date

Sep 19, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

A standard polyenergetic CT (computed tomography) procedure utilizes 100 ml of iodinated contrast. A recent world-wide shortage of iodine based intravenous contrast has highlighted the need to search for alternative methods or doses. Reducing iodinated IV contrast dose can mitigate IV contrast supply shortages and enable significant cost savings for the radiology practice and hospital system. In addition, decreased IV contrast dose can potentially reduce the rate of acute kidney injury, specifically in patients with decreased renal function. The purpose of the study is to determine whether low IV contrast dose CT with monoenergetic reconstruction can be use for presurgical planning of transcatheter valve replacement (TAVR) procedure.


Eligibility

Min Age: 18 YearsMax Age: 88 Years

Inclusion Criteria1

  • scheduled to receive TAVR abdominal CT

Exclusion Criteria3

  • cannot undergo CT scan
  • Allergy to intravenous contrast not controlled by steroids or benadryl
  • GFR\<30

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

COMBINATION_PRODUCTIodinated Contrast Agent (Omnipaque)

Standard dosage of Omnipaque for CT imaging is 100 ml. Cohort will be given a reduced dosage.

DEVICEDual Energy CT

Dual energy CT scanners enable monoenergetic CT image reconstruction which allows for improved iodine image contrast.


Locations(1)

University of Maryland Medical Center

Baltimore, Maryland, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05758701


Related Trials